Clareo Health | High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
Prostate cancer with localized, very-high risk, lymph-node positive, and/or metastatic (Stage IV) disease.
Being treated with ARPI therapy with intended duration ≥ 18 months.
Age \> 65 years old and at least one CV risk factor, or age 45-65 years with at least two CV risk factors:
* Hypertension
* Hyperlipidemia
* Diabetes mellitus
* Family history of early CAD (male first-degree relative (father or brother) with CAD before age 55; female first-degree relative (mother or sister) with CAD before age 65)
* Presence of coronary artery calcium (CAC) on chest CT imaging
ECOG 0-2
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
You may not be if
Prior ARPI therapy exposure \> 6 months duration.
Established care with cardio-oncologist (cardiologist with expertise in CV risks of cancer and cardiotoxic cancer therapies).
